Oramed Net Profit Margin from 2010 to 2024
| ORMP Stock | USD 2.37 0.02 0.85% |
Net Profit Margin | First Reported 2010-12-31 | Previous Quarter 4.12313433 | Current Value 4.33 | Quarterly Volatility 7.64425445 |
Check Oramed Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oramed Pharmaceuticals' main balance sheet or income statement drivers, such as Selling General Administrative of 8.8 M, Other Operating Expenses of 10.7 M or Research Development of 7.6 M, as well as many indicators such as Price To Sales Ratio of 74.82, Dividend Yield of 0.0 or PTB Ratio of 0.6. Oramed financial statements analysis is a perfect complement when working with Oramed Pharmaceuticals Valuation or Volatility modules.
Oramed | Net Profit Margin |
Latest Oramed Pharmaceuticals' Net Profit Margin Growth Pattern
Below is the plot of the Net Profit Margin of Oramed Pharmaceuticals over the last few years. It is the percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue. Oramed Pharmaceuticals' Net Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oramed Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Profit Margin | 10 Years Trend |
|
Net Profit Margin |
| Timeline |
Oramed Net Profit Margin Regression Statistics
| Arithmetic Mean | (9.41) | |
| Coefficient Of Variation | (81.20) | |
| Mean Deviation | 6.48 | |
| Median | (8.23) | |
| Standard Deviation | 7.64 | |
| Sample Variance | 58.43 | |
| Range | 22.4815 | |
| R-Value | 0.62 | |
| Mean Square Error | 38.40 | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | 1.07 | |
| Total Sum of Squares | 818.08 |
Oramed Net Profit Margin History
About Oramed Pharmaceuticals Financial Statements
Oramed Pharmaceuticals shareholders use historical fundamental indicators, such as Net Profit Margin, to determine how well the company is positioned to perform in the future. Although Oramed Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Oramed Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Oramed Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Profit Margin | 4.12 | 4.33 |
Pair Trading with Oramed Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oramed Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oramed Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Oramed Stock
Moving against Oramed Stock
| 0.58 | FNMFO | Federal National Mortgage | PairCorr |
| 0.47 | CIB | Bancolombia SA ADR | PairCorr |
| 0.44 | AVAL | Grupo Aval | PairCorr |
| 0.43 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
| 0.38 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
The ability to find closely correlated positions to Oramed Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oramed Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oramed Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oramed Pharmaceuticals to buy it.
The correlation of Oramed Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oramed Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oramed Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oramed Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.